Grufity logoGrufity logo

United Therapeutics Corp Stock Research

UTHR

255.65USD+0.41(+0.16%)Market Closed

Market Summary

USD255.65+0.41
Market Closed
0.16%

UTHR Alerts

UTHR Stock Price

UTHR RSI Chart

UTHR Valuation

Market Cap

11.6B

Price/Earnings (Trailing)

16.47

Price/Sales (Trailing)

6.26

EV/EBITDA

10.81

Price/Free Cashflow

17.15

UTHR Price/Sales (Trailing)

UTHR Profitability

EBT Margin

49.05%

Return on Equity

15.51%

Return on Assets

12.24%

Free Cashflow Yield

5.83%

UTHR Fundamentals

UTHR Revenue

Revenue (TTM)

1.9B

Revenue Y/Y

16.03%

Revenue Q/Q

10.52%

UTHR Earnings

Earnings (TTM)

707.4M

Earnings Y/Y

47.08%

Earnings Q/Q

106.29%

Price Action

52 Week Range

283.09
(Low)(High)

Last 7 days

-2.9%

Last 30 days

-7.4%

Last 90 days

-3.3%

Trailing 12 Months

28.0%

UTHR Financial Health

Current Ratio

9.68

UTHR Investor Care

Shares Dilution (1Y)

1.48%

Diluted EPS (TTM)

14.69

Peers (Alternatives to United Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
336.2B
1.2B
1.59% 13.84%
-159.75
269.02
17.64% -57.08%
257.0B
57.8B
-12.85% 4.71%
19.17
4.45
4.80% 77.95%
82.3B
15.0B
4.45% 23.71%
15.33
5.14
21.25% -46.28%
79.2B
8.7B
6.32% 26.84%
24.19
9.1
22.03% 50.41%
27.2B
960.9M
-1.80% 48.64%
-22.99
28.28
28.24% -41.08%
11.6B
1.9B
-7.43% 27.95%
16.47
6.26
12.37% 52.98%
10.6B
876.0M
-1.21% 59.04%
-14.8
12.1
35.70% -47.34%
MID-CAP
4.7B
504.0K
-2.18% 252.25%
-17.17
2.5K
-66.53% -15.89%
3.3B
343.4M
2.10% -31.74%
-4.92
9.72
-4.50% -90.69%
3.1B
-
19.78% -55.50%
-4.19
917.1
- -52.72%
2.7B
272.3M
-2.18% -43.09%
-3.82
10.07
-18.36% -74.56%
SMALL-CAP
1.7B
191.8M
-17.30% 147.86%
25.21
8.8
43.59% 60.82%
350.9M
93.0M
0.18% -51.94%
-1.84
3.77
-19.83% -30.37%
20.6M
-
13.38% -60.95%
-0.49
19.11
-77.61% 5.14%
4.2M
-
4.24% 28.70%
-0.01
63.29
26.15% -23.38%

Financials for United Therapeutics

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue4.0%1,8601,7891,7681,6861,655
Gross Profit3.7%1,7231,6611,6331,5631,577
  S&GA Expenses-4.3%480501444--
  R&D Expenses-4.0%312325305540583
Costs and Expenses-1.6%8869008601,1301,204
EBITDA12.9%988875939662-
EBITDA Margin8.6%0.53*0.49*0.53*0.39*-
Earnings Before Taxes13.4%912804870594568
EBT Margin9.1%0.49*0.45*0.49*0.35*-
Interest Expenses22.8%2520191919
Net Income12.1%707631687476462
Net Income Margin7.8%0.38*0.35*0.39*0.28*-
Free Cahsflow4.2%679652673477-
* denotes actual numbers (not divided by Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets4.3%5,7825,5435,3605,1695,049
  Current Assets13.9%3,0562,6842,5872,3242,386
    Cash Equivalents21.6%967795813895909
  Inventory1.2%9190889497
  Net PPE6.2%841791784781727
  Goodwill-28----
Liabilities-0.4%1,2191,2251,1841,2101,219
  Current Liabilities-4.7%316332293305320
Shareholder's Equity5.6%4,5624,3184,1763,9593,830
  Retained Earnings5.1%4,9104,6714,5554,3154,203
  Additional Paid-In Capital1.0%2,3152,2922,2542,2452,226
Accumulated Depreciation3.4%377364352342-
Shares Outstanding0.2%4645454545
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations9.4%849776797598550
  Share Based Compensation-23.7%8711477139188
Cashflow From Investing14.8%-818.00-959.90-839.80-486.90-354.90
Cashflow From Financing-25.9%2737244543

Risks for UTHR

What is the probability of a big loss on UTHR?

73.8%


Probability that United Therapeutics stock will be more than 20% underwater in next one year

31.1%


Probability that United Therapeutics stock will be more than 30% underwater in next one year.

12.7%


Probability that United Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does UTHR drawdown profile look like?

Y-axis is the maximum loss one would have experienced if United Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for UTHR

Cumulative Returns on UTHR

16.9%


10-Year Cumulative Returns

11.5%


7-Year Cumulative Returns

15.2%


5-Year Cumulative Returns

36.5%


3-Year Cumulative Returns

What are the long-term rolling returns for UTHR?

FIve years rolling returns for United Therapeutics.

Annualized Returns

Which funds bought or sold UTHR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-02-06
WESTPAC BANKING CORP
new
-
2,600,980
2,600,980
0.04%
2023-02-06
Glassman Wealth Services
reduced
-2.34
7,761
34,761
0.01%
2023-02-06
SYNOVUS FINANCIAL CORP
new
-
250,281
250,281
-%
2023-02-06
Daiwa Securities Group Inc.
added
8.28
16,000
51,000
-%
2023-02-06
LOS ANGELES CAPITAL MANAGEMENT LLC
added
109.49
18,216,400
28,436,400
0.14%
2023-02-06
Retirement Systems of Alabama
reduced
-0.99
8,798,350
36,727,300
0.16%
2023-02-06
Symmetry Investments LP
new
-
4,629,000
4,629,000
1.24%
2023-02-06
Bogart Wealth, LLC
new
-
10,289
10,289
-%
2023-02-06
Parallel Advisors, LLC
added
5.03
37,483
133,483
0.01%
2023-02-06
Pacer Advisors, Inc.
reduced
-87.71
-14,718,000
2,871,000
0.01%

1–10 of 46

Latest Funds Activity

Are funds buying UTHR calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own UTHR
No. of Funds

United Therapeutics News

MarketBeat

Creative Planning Makes New $226000 Investment in United ....

MarketBeat,
21 hours ago

GuruFocus.com

Top 5 4th Quarter Trades of TOBAM.

GuruFocus.com,
5 days ago

Yahoo Finance

Schedule 13G FIlings of United Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 06, 2023
wellington management group llp
5.64%
2,569,263
SC 13G
Feb 02, 2023
rothblatt martine a
8.0%
3,919,603
SC 13G/A
Jan 24, 2023
blackrock inc.
9.9%
4,510,211
SC 13G/A
Feb 11, 2022
renaissance technologies llc
6.48%
2,917,191
SC 13G/A
Feb 11, 2022
avoro capital advisors llc
6.7%
3,035,000
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 04, 2022
rothblatt martine a
8.5%
4,118,487
SC 13G/A
Feb 03, 2022
blackrock inc.
9.4%
4,239,175
SC 13G/A
Mar 01, 2021
rothblatt martine a
7.6%
3,629,486
SC 13G/A
Feb 12, 2021
avoro capital advisors llc
6.4%
2,850,000
SC 13G

UTHR Fair Value

Recent SEC filings of United Therapeutics

View All Filings
Date Filed Form Type Document
Feb 07, 2023
4
Insider Trading
Feb 06, 2023
SC 13G
Major Ownership Report
Feb 06, 2023
SC 13G/A
Major Ownership Report
Feb 03, 2023
SC 13G/A
Major Ownership Report
Feb 03, 2023
SC 13G
Major Ownership Report
Feb 03, 2023
4
Insider Trading
Feb 02, 2023
4
Insider Trading
Feb 02, 2023
4
Insider Trading
Feb 02, 2023
SC 13G/A
Major Ownership Report
Feb 02, 2023
SC 13G/A
Major Ownership Report

Latest Insider Trading transactions for UTHR

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-02-02
MAHON PAUL A
sold
-1,527,790
254.632
-6,000
evp & general counsel
2023-02-02
ROTHBLATT MARTINE A
sold
-2,052,910
256.614
-8,000
chairperson & ceo
2023-02-02
MAHON PAUL A
acquired
721,560
120.26
6,000
evp & general counsel
2023-02-02
ROTHBLATT MARTINE A
acquired
904,640
113.08
8,000
chairperson & ceo
2023-02-01
SULLIVAN LOUIS W
acquired
92,610
132.3
700
-
2023-02-01
SULLIVAN LOUIS W
sold
-182,931
261.33
-700
-
2023-02-01
ROTHBLATT MARTINE A
acquired
904,640
113.08
8,000
chairperson & ceo
2023-02-01
ROTHBLATT MARTINE A
sold
-2,079,600
259.951
-8,000
chairperson & ceo
2023-01-31
ROTHBLATT MARTINE A
acquired
904,640
113.08
8,000
chairperson & ceo
2023-01-31
ROTHBLATT MARTINE A
sold
-2,092,020
261.503
-8,000
chairperson & ceo

1–10 of 50

Martine A. Rothblatt
960
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

UTHR Income Statement

2022-09-30
Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:    
Total revenues$ 516.0$ 444.7$ 1,444.8$ 1,270.3
Operating expenses:    
Cost of product sales$ 37.2$ 27.7$ 92.8$ 87.9
Cost, product and serviceNet product salesNet product salesNet product salesNet product sales
Research and development$ 66.1$ 79.2$ 229.0$ 457.2
Selling, general, and administrative98.4109.1318.9339.1
Total operating expenses201.7216.0640.7884.2
Operating income314.3228.7804.1386.1
Interest income13.33.824.412.5
Interest expense(9.2)(4.6)(20.1)(13.9)
Other (expense) income, net(5.9)(23.5)(34.9)71.0
Impairments of investments in privately-held companies0.00.0(1.7)(2.3)
Total other (expense) income, net(1.8)(24.3)(32.3)67.3
Income before income taxes312.5204.4771.8453.4
Income tax expense(73.2)(41.7)(176.6)(89.8)
Net income$ 239.3$ 162.7$ 595.2$ 363.6
Net income per common share:    
Basic (in dollars per share)$ 5.26$ 3.62$ 13.14$ 8.12
Diluted (in dollars per share)$ 4.91$ 3.42$ 12.35$ 7.72
Weighted average number of common shares outstanding:    
Basic (in shares)45.544.945.344.8
Diluted (in shares)48.747.648.247.1
Net product sales    
Revenues:    
Total revenues$ 516.0$ 444.7$ 1,434.8$ 1,270.3
Other    
Revenues:    
Total revenues$ 0.0$ 0.0$ 10.0$ 0.0

UTHR Balance Sheet

2022-09-30
Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 966.8$ 894.8
Marketable investments1,648.81,035.9
Accounts receivable, no allowance for 2022 and 2021231.7198.7
Inventories, net91.093.8
Other current assets118.1100.4
Total current assets3,056.42,323.6
Marketable investments1,443.81,649.9
Goodwill and other intangible assets, net44.544.6
Property, plant, and equipment, net840.8780.9
Deferred tax assets, net281.3261.9
Other non-current assets114.8108.2
Total assets5,781.65,169.1
Current liabilities:  
Accounts payable and accrued expenses220.1174.6
Share tracking awards plan60.1102.4
Other current liabilities35.728.4
Total current liabilities315.9305.4
Line of credit800.0800.0
Other non-current liabilities103.5104.8
Total liabilities1,219.41,210.2
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, par value $.01, 10,000,000 shares authorized, no shares issued0.00.0
Common stock, par value $.01, 245,000,000 shares authorized, 72,182,311 and 71,727,021 shares issued, and 45,563,095 and 45,107,805 shares outstanding at September 30, 2022 and December 31, 2021, respectively0.70.7
Additional paid-in capital2,314.62,245.4
Accumulated other comprehensive loss(84.1)(23.0)
Treasury stock, 26,619,216 shares at September 30, 2022 and December 31, 2021(2,579.2)(2,579.2)
Retained earnings4,910.24,315.0
Total stockholders’ equity4,562.23,958.9
Total liabilities and stockholders’ equity$ 5,781.6$ 5,169.1